Search Result

Results for "

LSDs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (7) Adrenergic Receptor (2) Amyloid-β (1) Apoptosis (38) Arrestin (1) Bcl-2 Family (2) Biochemical Assay Reagents (2) Caspase (3) CD44 (1) Ceramidase (1) DNA/RNA Synthesis (1) Dopamine Receptor (5) Drug Derivative (4) Drug Metabolite (2) E1/E2/E3 Enzyme (1) EGFR (2) Estrogen Receptor/ERR (1) G protein-coupled Bile Acid Receptor 1 (2) GABA Receptor (2) Glucosylceramide Synthase (GCS) (1) Glycosidase (4) Glycosyltransferase (1) HDAC (11) Histone Demethylase (146) Histone Methyltransferase (4) HSP (1) HSV (2) IAP (1) Isotope-Labeled Compounds (3) Ligands for Target Protein for PROTAC (2) MAP3K (5) MDM-2/p53 (5) Microtubule/Tubulin (2) Molecular Glues (2) Monoamine Oxidase (21) Notch (2) PD-1/PD-L1 (4) Phosphatase (2) PROTAC-Linker Conjugates for PAC (1) PROTACs (4) Reference Standards (8) ROS Kinase (5) TGF-beta/Smad (3) TLK (1) TNF Receptor (1) Wee1 (1)
By Research Areas:	Cancer (134) Cardiovascular Disease (13) Endocrinology (5) Infection (9) Inflammation/Immunology (10) Metabolic Disease (11) Neurological Disease (33)
Click Chemistry:	Alkynes (3)

182

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17447A

Tranylcypromine hydrochloride 5+ Cited Publications SKF 385 hydrochloride	Monoamine Oxidase Ligands for Target Protein for PROTAC Histone Demethylase	Neurological Disease
Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 *(LSD1/BHC110)* and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC₅₀s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression .

HY-112623

Vafidemstat 2 Publications Verification ORY-2001	Histone Demethylase Monoamine Oxidase	Neurological Disease
Vafidemstat (ORY-2001) is an oral, brain penetrant, dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor .

HY-12635

SP2509 10+ Cited Publications	Histone Demethylase Apoptosis	Cancer
SP2509 is a potent and selective antagonist of lysine specific demethylase 1 (LSD1) with an IC₅₀ of 13 nM .

HY-100546A

*GSK-LSD1 dihydrochloride* 10+ Cited Publications	Histone Demethylase Monoamine Oxidase	Cancer
GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC₅₀ of 16 nM.

HY-111048

Corin 5 Publications Verification	Histone Demethylase HDAC	Cancer
Corin is a dual inhibitor of histone lysine specific demethylase *(LSD1)* and histone deacetylase (HDAC), with a K_i(inact) of 110 nM for LSD1 and an IC₅₀ of 147 nM for HDAC1.

HY-18632A

GSK2879552 dihydrochloride Maximum Cited Publications 19 Publications Verification	Histone Demethylase	Cancer
GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A), with potential antineoplastic activity .

HY-101075

L-690330 1 Publications Verification	Phosphatase	Others
L-690330 is a competitive inhibitor of inositol monophosphatase (IMPase) with K_is of 0.27 and 0.19 μM for recombinant human and bovine IMPase, 0.30 and 0.42 μM for human and bovine frontal cortex IMPase, respectively. L-690330 exhibits 10-fold more sensitive than mouse and rat IMPase .

HY-121675

2-Bromo-LSD BOL-148; Bromolysergide	5-HT Receptor G protein-coupled Bile Acid Receptor 1	Neurological Disease
2-Bromo-LSD (BOL-148) is a blood-brain barrier-permeable 5-HT_2A partial agonist and competitive partial antagonist. 2-Bromo-LSD acts as both a potent partial agonist (with an EC₅₀ of 0.81 nM for Gq dissociation) and a potent partial antagonist (with a K_B of 0.18 nM for Gq dissociation) at the 5-HT_2A receptor. 2-Bromo-LSD exhibits partial agonist activity at multiple aminergic GPCRs, including 5-HT_2A. 2-Bromo-LSD lacks 5-HT_2B agonist activity. 2-Bromo-LSD induces dendritogenesis and spinogenesis. 2-Bromo-LSD reverses the behavioral effects of chronic stress and increases active coping behaviors in mice .

HY-110130

RN-1 dihydrochloride	Histone Demethylase	Cardiovascular Disease Cancer
RN-1 dihydrochloride is a potent, brain-penetrant, irreversible and selective lysine-specific demethylase 1 (LSD1) inhibitor with an IC₅₀ of 70 nM. RN-1 dihydrochloride exhibits selectivity for LSD1 over MAO-A and MAO-B with IC₅₀ values of 0.51 μM and 2.785 μM respectively .

HY-138218

ALD-52 1-Acetyl-LSD	Drug Derivative 5-HT Receptor	Neurological Disease
ALD-52 (1-Acetyl-LSD) is a prodrug for LSD. ALD-52 shows an affinity to 5-HT_1A, 5-HT_2A and 5-HT_2C with a sub>D values of 1054, 174 and 10.2 nM, respectively. ALD-52 is converted to LSD and induces a head-twitch response (HTR) in vivo. ALD-52 can be used for hallucinogen research .

HY-164099

LSD1/HDAC6-IN-2	HDAC Monoamine Oxidase Histone Demethylase	Cancer
LSD1/HDAC6-IN-2 (JBI-802) is an orally active *LSD1/HDAC6/MAO-A* inhibitor, with IC₅₀ values of 5 nM, 11 nM, and 5 nM, respectively. LSD1/HDAC6-IN-2 can inhibit the growth of multiple myeloma cells MM.1S, MM.1R, and RPMI-8226. LSD1/HDAC6-IN-2 can be used for research on diseases such as acute myeloid leukemia and lymphoma .

HY-P4091

*LSD*	Biochemical Assay Reagents	Cancer
LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics .

HY-W767767

*2-Oxo-3-hydroxy-LSD-d10*	Isotope-Labeled Compounds Drug Metabolite	Neurological Disease
2-Oxo-3-hydroxy-LSD-d₁₀ is the deuterium labeled 2-Oxo-3-hydroxy-LSD (HY-137386). 2-Oxo-3-hydroxy-LSD is a metabolite of Lysergic acid diethylamide .

HY-176875

*CoREST/LSD1 degrader-1*	Molecular Glues	Cancer
CoREST/LSD1 degrader-1 (Compound 4) is a molecular glue degrader targeting the KBTBD4 E3 ubiquitin ligase. CoREST/LSD1 degrader-1 is promising for research of KBTBD4-mutant driven cancers (e.g., medulloblastoma) and epigenetic dysregulation disorders .

HY-15313C

CBB1007 trihydrochloride 2 Publications Verification	Histone Demethylase	Metabolic Disease Cancer
CBB1007 trihydrochloride is a reversible and selective *LSD1* inhibitor with an IC₅₀ of 5.27 µM for human LSD1. CBB1007 trihydrochloride significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 trihydrochloride shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 trihydrochloride is studied in non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma .

HY-178826

LSD1-IN-45	Ligands for Target Protein for PROTAC Histone Demethylase	Inflammation/Immunology Cancer
LSD1-IN-45 is an *LSD1* inhibitor and a ligand for the target protein for PROTAC. LSD1-IN-45 can be used to synthesize PROTAC LD-110 (HY-178825) .

HY-100859

LSD1-IN-5	Histone Demethylase	Cancer
LSD1-IN-5 (Compound 4e) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC₅₀ of 121 nM. LSD1-IN-5 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1 .

HY-100546

*GSK-LSD1*	Histone Demethylase	Infection Metabolic Disease Cancer
GSK-LSD1, a chemical probe, is a *LSD1* inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis .

HY-W025799

N-Benzylideneaniline N-Benzalaniline; N-Phenylbenzylimine	Histone Demethylase	Cancer
N-Benzylideneaniline is an inhibitor of xylinostilbene-α,β-dioxygenase (LSD) .

HY-137386

2-Oxo-3-hydroxy-LSD	Drug Metabolite	Neurological Disease
2-Oxo-3-hydroxy-LSD is a metabolite of Lysergic acid diethylamide .

HY-117226A

GSK 690 Hydrochloride 3 Publications Verification	Histone Demethylase	Others
GSK 690 (Hydrochloride) is a reversible inhibitor of lysine specific demethylase 1 *(LSD1), with a K_d* value of 9 nM and a biochemical IC₅₀ of 37 nM.

HY-151194

LSD1/2-IN-4	Histone Demethylase	Cancer
LSD1/2-IN-4, a PCPA derivative, is an inhibitor of lysine-specific demethylase 1 (LSD1) and lysine-specific demethylase 2 (LSD2). LSD1/2-IN-4 inhibits LSD1 and LSD2 with K_i values of 0.11 μM and 130 μM, respectively. LSD1/2-IN-4 can be used for the research of several cancers including T-cell acute lymphoblastic leukemia (TALL) .

HY-175184

LSD1-IN-44	Histone Demethylase	Infection
LSD1-IN-44 (Compound 19) is a *LSD1* inhibitor with an IC₅₀ of 0.02  μM for LSD1-CoREST enzymatic complex. LSD1-IN-44 has significant antischistosomal activity against transformed schistosomula (NTS) and Schistosoma mansoni adult worms while showing a delayed onset of action towards juvenile forms. LSD1-IN-44 has no significant toxicity to human cells. LSD1-IN-44 can be used for schistosomiasis research .

HY-179229

LSD1-IN-47	PROTACs Histone Demethylase	Cancer
LSD1-IN-47 is a highly efficient PROTAC degrader targeting *LSD1* (IC₅₀ = 43 nM). LSD1-IN-47 does not alter LSD1 protein levels and does not increase the histone marker H3K4me2. LSD1-IN-47 can be used for the study of colon carcinoma .

HY-155115

LSD1-IN-27 1 Publications Verification	Histone Demethylase PD-1/PD-L1	Cancer
LSD1-IN-27 is an orally active *LSD1* inhibitor (IC₅₀: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer .

HY-149978

LSD1-IN-26	Histone Demethylase Monoamine Oxidase Apoptosis Bcl-2 Family IAP Caspase	Cancer
LSD1-IN-26 (compound 12u) is a potent *LSD1* inhibitor, with an IC₅₀ of 25.3 nM. LSD1-IN-26 also inhibits MAO-A (IC₅₀=1234.57 nM) and MAO-B (IC₅₀=3819.27 nM). LSD1-IN-26 significantly induces apoptosis in MGC-803 cells. LSD1-IN-26 can be used for gastric cancer research .

HY-179339

LSD1-IN-46	Histone Demethylase	Cancer
LSD1-IN-46 is a potent and orally active Lysine-specific demethylase 1 (LSD1) inhibitor with an IC₅₀ of 0.082 μM. LSD1-IN-46 interrupts the β-catenin-mediated transcriptional program, thereby suppressing the stemness of gastric cancer cells. LSD1-IN-46 exhibits strong anti-tumor activity. LSD1-IN-46 can be used for the research of gastric cancer .

HY-176254

LSD1-IN-43	Histone Demethylase Amyloid-β	Neurological Disease
LSD1-IN-43 is a highly selective, reversible, orally active and brain-penetrant *LSD1* inhibitor with an IC₅₀ value of 0.8 μM. LSD1-IN-43 has low inhibitory activity against MAO-A and MAO-B, two homologs of LSD1. LSD1-IN-43 significantly inhibits Aβ aggregation and enhances Aβ-induced neuronal cell viability. LSD1-IN-43 can be used for the study of Alzheimer’s disease (AD).

HY-100860

LSD1-IN-6	Histone Demethylase	Cancer
LSD1-IN-6 (Compound 4m) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC₅₀ of 123 nM. LSD1-IN-6 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1 .

HY-149968

LSD1-IN-25	Histone Demethylase Apoptosis	Cancer
LSD1-IN-25 (Compound 9j) is a potent, selective and orally active *LSD₁* inhibitor with an IC₅₀ of 46 nM (K_i = 30.3 nM). LSD1-IN-25 induces cancer cell apoptosis .

HY-12645

NCL1	Histone Demethylase	Cancer
NCL1 is a phenylcyclopropylamine (PCPA)-based Lysine-specific demethylase 1 (LSD1) inhibitor. NCL1 selectively inhibits LSD1 in preference to LSD2, with IC₅₀ values of 2.5 and 26 μM for LSD1 and LSD2, respectively .

HY-175671

LSD1/HDAC-IN-3	HDAC Histone Demethylase	Neurological Disease
LSD1/HDAC-IN-3 is a inhibitor targeting class I HDAC and *LSD1* enzymes. LSD1/HDAC-IN-3 inhibits HDAC1, HDAC2, HDAC3, and *LSD1* with IC₅₀ values of 1702 nM, 842 nM, 358 nM, and 1074 nM, respectively. LSD1/HDAC-IN-3 exhibits antioxidant effects in H2O2-stressed ARPE-19 and 661W retinal cells, increasing levels of acetylated and methylated histone H3. LSD1/HDAC-IN-3 enhances photoreceptor survival in the rd10 mouse model of retinitis pigmentosa. LSD1/HDAC-IN-3 can be used for the study of inherited retinal diseases such as retinitis pigmentosa (RP) .

HY-149595

LSD1-UM-109	Histone Demethylase	Cancer
LSD1-UM-109 is a ighly potent and reversible *LSD1* inhibitor with an IC₅₀ of 3.1 nM. LSD1-UM-109 inhibits cell growth with IC₅₀ values of 0.6 nM in the MV4;11 acute leukemia cell line and 1.1 nM in the H1417 small-cell lung cancer cell line .

HY-112304

NCD38 TFA	Histone Demethylase	Others
NCD38 TFA is a *LSD1*-selective inhibitor .

HY-149213

LSD1/TLK1-IN-1 J54; J3-54	Histone Demethylase TLK	Cancer
LSD1/TLK1-IN-1 is an orally active *LSD1, TLK1, TLK2, TTK* inhibitor with an *LSD1* IC₅₀ of 0.247 μM. LSD1/TLK1-IN-1 suppresses phosphorylation of Nek1 at T141 and Rad9 at S328, abrogates the TLK1>Nek1>ATR>Chk1 axis, protects H3K4me1/2 from demethylation, and does not affect *LSD2, MAO-A, or MAO-B. LSD1/TLK1-IN-1 induces apoptosis, bypasses cell-cycle arrest, suppresses tumor growth, acts as a weak D4R* antagonist, downregulates PD-L1 expression, enhances T-cell killing response, inhibits gastric cancer cell proliferation, shows minimal toxicity, and has no significant effect on normal prostate cells. LSD1/TLK1-IN-1 can be used for the research of prostate cancer and gastric cancer .

HY-176283

*Tubulin/LSD1-IN-1*	Microtubule/Tubulin Histone Demethylase Apoptosis Wee1 Bcl-2 Family Caspase	Cancer
Tubulin/LSD1-IN-1 is an effective dual inhibitor of Tubulin polymerization and *LSD1* (IC₅₀ = 1.72 μM). Tubulin/LSD1-IN-1 has broad-spectrum antiproliferative activity against cancer cell lines. Tubulin/LSD1-IN-1 inhibits tubulin polymerization by targeting colchicine binding sites, thereby disrupting the microtubule network in gastric cancer cells. Tubulin/LSD1-IN-1 increases the methylation levels of H3K4me1/2 and H3K9me2/3, thereby achieving epigenetic regulation. Tubulin/LSD1-IN-1 induces G2/M arrest, promotes apoptosis, and effectively inhibits colony formation of gastric cancer cells .

HY-146380

S1427	Histone Demethylase	Cancer
S1427 is a tranylcypromine-derived *LSD1* inhibitor with the IC₅₀ of 390 nM and K_i of 80 nM. S1427 exhibits desirable hERG channel inhibition and microsomal stability profiles. Inhibition of LSD1 partially reduces the proliferation of cancer cells .

HY-123867

NCD-25	Histone Demethylase	Others
NCD-25 is a selective inhibitor of *LSD1* with an IC₅₀ of 0.48 μM.

HY-15774

CBB1003	Histone Demethylase	Cancer
CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

HY-143238

FY-56	Histone Demethylase	Cancer
FY-56 is a highly potent and selective *LSD1/KDM1A* inhibitor (IC₅₀=42 nM) and exhibits high selectivity over MAO-A/B. FY-56 induces differentiation of MOLM-13 and MV4-11 cell and has the potential for AML research .

HY-161849

LSD1-IN-31	Histone Demethylase	Metabolic Disease
LSD1-IN-31 (compound 11e) can directly bind to LSD1/CoREST complex to reduce LSD1 demethylation enzymatic activity. LSD1-IN-31 inhibits LSD1 demethylation activity and influences its downstream IκB/NF-κB signaling pathway. LSD1-IN-31 inhibits osteoclastic bone loss in vitro and in vivo. LSD1-IN-31 can be used for osteoporosis research .

HY-168504

LSD1-IN-36	Histone Demethylase Apoptosis	Cancer
LSD1-IN-36 is a potent *LSD1* inhibitor with an IC₅₀ value of 0.8 nM. LSD1-IN-36 induces apoptosis and arrests the cell cycle. LSD1-IN-36 shows antitumor activity .

HY-151192

LSD1/2-IN-3	Histone Demethylase	Cancer
LSD1/2-IN-3 is a selective inhibitor of lysine-specific demethylase 1 (LSD1), with a K_i value of 11 nM instead of 7 μM for *LSD2. There is aberrant expression of LSD1* in cancer stem cells, LSD1/2-IN-1 inhibits *LSD1* cell proliferation .

HY-152032

LSD1-IN-23	Histone Demethylase	Cancer
LSD1-IN-23 is a competitive/non-competitive mixed inhibitor of lysine specific demethylase 1 (LSD1). LSD1-IN-23 has LSD1 inhibitory activity with an IC₅₀ value of 0.58 μM. LSD1-IN-23 can be used for the research of neuroblastoma (NB) .

HY-173123

LSD1-IN-40	Histone Demethylase Apoptosis	Cancer
LSD1-IN-40 (Compound 9e) is a potent *LSD1* inhibitor, with an IC₅₀ of 9.85 nM. LSD1-IN-40 exhibits exceptional selectivity for LSD1 over both MAOs and hERG. LSD1-IN-40 exhibits significant inhibitory activity against leukemia cells (MV-4-11, HL-60, and THP-1 cells). LSD1-IN-40 can induce apoptosis in MV-4-11 cells. LSD1-IN-40 has the potential for the research of acute myeloid leukemia .

HY-144758

LSD1-IN-17	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-17 (compound 5b) is a potent *LSD1* inhibitor. LSD1-IN-17 can inhibit *LSD1-CoREST, MAO-A* and MAO-B, with IC₅₀ values of 0.005, 0.028, and 0.820 μM, respectively. LSD1-IN-17 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 17.2 μM .

HY-144756

LSD1-IN-15	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-15 (compound 1b) is a potent *LSD1* inhibitor. LSD1-IN-15 can inhibit *LSD1-CoREST, MAO-A* and MAO-B, with IC₅₀ values of 0.149, 0.028, and 0.327 μM, respectively. LSD1-IN-15 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 9.9 μM .

HY-144757

LSD1-IN-16	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-16 (compound 4b) is a potent *LSD1* inhibitor. LSD1-IN-16 can inhibit *LSD1-CoREST, MAO-A* and MAO-B, with IC₅₀ values of 0.015, 0.024, and 0.366 μM, respectively. LSD1-IN-16 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 15.2 μM .

HY-144675A

LSD1-IN-13 hydrochloride	Histone Demethylase	Cancer
LSD1-IN-13 hydrochloride (compound 7e) is an orally active and potent *LSD1* inhibitor, with an IC₅₀ of 24.43 nM. LSD1-IN-13 hydrochloride can activate CD86 expression, with an EC₅₀ of 470 nM. LSD1-IN-13 hydrochloride induces differentiation of AML (acute myeloid leukemia) cell lines .

HY-144675

LSD1-IN-13	Histone Demethylase	Cancer
LSD1-IN-13 (compound 7e) is an orally active and potent *LSD1* inhibitor, with an IC₅₀ of 24.43 nM. LSD1-IN-13 can activate CD86 expression, with an EC₅₀ of 470 nM. LSD1-IN-13 induces differentiation of AML (acute myeloid leukemia) cell lines .

Cat. No.	Product Name	Target	Research Area

HY-P4091

*LSD*	Biochemical Assay Reagents	Cancer
LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics .

HY-P4091A

LSD acetate	Biochemical Assay Reagents	Cancer
LSD acetate is a peptide. LSD acetate can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD acetate can reduce the number of tumor lymphatics. LSD acetate can be used in the research of targeted therapy and diagnosis of tumor lymphatics .

HY-P10819

S9-CMC1 TFA	Histone Demethylase Apoptosis	Cancer
S9-CMC1 TFA is a covalent peptide lysine-specific demethylase 1 (LSD1) inhibitor with an IC₅₀ value of 2.53 μM. S9-CMC1 TFA specifically recognizes Cys360 in the enzyme-active region. S9-CMC1 TFA inhibits *LSD1* activity, increasing H3K4me1 and H3K4me2 levels, leading to G1 cell cycle arrest and apoptosis and inhibiting cell proliferation. S9-CMC1 TFA significantly inhibits tumor growth in A549 xenograft animal models .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2037

Higenamine 5+ Cited Publications Norcoclaurine; Demethyl-Coclaurine	Alkaloids Structural Classification Classification of Application Fields Ranunculaceae Phenols Polyphenols Aconitum carmichaeli Debx. Plants Isoquinoline Alkaloids Disease Research Fields Endocrinology Source Classification	MAP3K MDM-2/p53 Adrenergic Receptor ROS Kinase Apoptosis
Higenamine (Norcoclaurine), a β2-AR agonist with antioxidant capability, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine is also a α1-adrenergic receptor antagonist with hypotensive effect. is a selective *LSD1* inhibitor (IC₅₀=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine protects myocyte Apoptosis and ischemia/reperfusion (I/R) injury through selective activation of beta2-adrenergic receptor (β2-AR). Higenamine also reduces I/R-induced myocardial infarction in mice. Higenamine can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

HY-N2037A

Higenamine hydrochloride 5+ Cited Publications Norcoclaurine hydrochloride	Structural Classification Classification of Application Fields Plants Lindera aggregata (Sims) Kosterm. Alkaloids Phenols Polyphenols Lauraceae Isoquinoline Alkaloids Disease Research Fields Endocrinology Source Classification Cancer	MAP3K MDM-2/p53 ROS Kinase Apoptosis
Higenamine hydrochloride is a selective *LSD1* inhibitor (IC₅₀=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine (Norcoclaurine) can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine hydrochloride protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine hydrochloride can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

HY-N2037R

Higenamine (Standard) Norcoclaurine (Standard); Demethyl-Coclaurine (Standard)	Alkaloids Structural Classification Ranunculaceae Phenols Polyphenols Aconitum carmichaeli Debx. Plants Isoquinoline Alkaloids Source Classification	Reference Standards MAP3K MDM-2/p53 Adrenergic Receptor ROS Kinase Apoptosis
Higenamine (Norcoclaurine), a β2-AR agonist with antioxidant capability, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine is also a α1-adrenergic receptor antagonist with hypotensive effect. is a selective LSD1 inhibitor (IC50=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine protects myocyte Apoptosis and ischemia/reperfusion (I/R) injury through selective activation of beta2-adrenergic receptor (β2-AR). Higenamine also reduces I/R-induced myocardial infarction in mice. Higenamine can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

HY-N2037AR

Higenamine hydrochloride (Standard) Norcoclaurine hydrochloride (Standard)	Alkaloids Structural Classification Phenols Polyphenols Plants Lauraceae Isoquinoline Alkaloids Lindera aggregata (Sims) Kosterm. Source Classification	MAP3K Reference Standards MDM-2/p53 ROS Kinase Apoptosis
Higenamine (hydrochloride) (Standard) is the analytical standard of Higenamine (hydrochloride). This product is intended for research and analytical applications. Higenamine hydrochloride is a selective LSD1 inhibitor (IC50=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine (Norcoclaurine) can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine hydrochloride protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine hydrochloride can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

HY-N18236

3β-Acetoxyl-atractylenolide I	Structural Classification Terpenoids Diterpenoids Astragalus caprinus L. Plants Compositae Source Classification	Histone Demethylase
3β-Acetoxyl-atractylenolide I is a *LSD1* inhibitor with an IC₅₀ of 57 μM. 3β-Acetoxyl-atractylenolide I blocks tumor growth, metastasis and invasion. 3β-Acetoxyl-atractylenolide I is used in the research of various cancers including prostate cancer, breast cancer, neuroblastoma, gastric cancer, colon cancer, bladder cancer, esophageal cancer, acute myeloid leukemia and retinoblastoma .

Cat. No.	Product Name	Chemical Structure

HY-W767767

*2-Oxo-3-hydroxy-LSD-d10*
2-Oxo-3-hydroxy-LSD-d₁₀ is the deuterium labeled 2-Oxo-3-hydroxy-LSD (HY-137386). 2-Oxo-3-hydroxy-LSD is a metabolite of Lysergic acid diethylamide .

HY-B1018AS

Phenelzine-d5 sulfate

Phenelzine-d5 sulfate is the deuterium labeled Phenelzine sulfate (HY-B1018A). Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active monoamine oxidase (MAO-A and MAO-B) inhibitor. Phenelzine sulfate inhibits GABA transaminase and primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits LSD1 (Ki: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine). Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer .

HY-17447AS

(1S,2R)-Tranylcypromine-d5 hydrochloride

(1S,2R)-Tranylcypromine-d₅ (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride . Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC₅₀s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression .

HY-17447SA

Tranylcypromine-d5 hydrochloride

Tranylcypromine-d₅ (hydrochloride) is a deuterium labeled (rel)-Tranylcypromine hydrochloride. Tranylcypromine hydrochloride is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hydrochloride is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis .

HY-168968S

ZJY-54
ZJY-54 is an orally active dual-target inhibitor of *EGFR/LSD1, with IC₅₀* values of 3.8 nM and 0.6 μM, respectively. ZJY-54 can inhibit the proliferation of non-small cell lung cancer cells, induce the accumulation of H3K4me2 and H3K9me2, and inhibit the phosphorylation of the EGFR signaling pathway. ZJY-54 has anti-tumor activity .

HY-N2037AS1

Higenamine-d4-1 hydrochloride

Higenamine-d₄-1 (Norcoclaurine-d₄-1) hydrochloride is deuterium labeled Higenamine (hydrochloride). Higenamine hydrochloride is a selective LSD1 inhibitor (IC₅₀=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine (Norcoclaurine) can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine hydrochloride protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine hydrochloride can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

Cat. No.	Product Name		Classification

HY-145259

HDAC6-IN-3		Alkynes
HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active HDAC6 inhibitor with IC₅₀s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective MAO-A (IC₅₀=0.79 μM) and *LSD1* inhibitor . HDAC6-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-169098

*HSP90/LSD1-IN-1*		Alkynes
HSP90/LSD1-IN-1 (compound 6) is a *HSP90/LSD1* dual inhibitor. HSP90/LSD1-IN-1 inhibits the proliferation of prostate cancer cell lines PC-3 and DU145, with GI₅₀ values of 0.24 and 0.30 μM, respectively .

HY-175185

MC3935		Alkynes
MC3935 is a *LSD1* inhibitor with an IC₅₀ of 0.52  μM for LSD1-CoREST enzymatic complex. MC3935 has significant antischistosomal activity against transformed schistosomula (NTS) and Schistosoma mansoni adult worms while showing a delayed onset of action towards juvenile forms. MC3935 has no significant toxicity to human cells. MC3935 can be used for schistosomiasis research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks